董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marc Elia | 男 | Director | 50 | 8.25万美元 | 190.86 | 2026-01-12 |
| Ajay Royan | 男 | Director and Chairman | 46 | 12.33万美元 | 650.56 | 2026-01-12 |
| Clive Meanwell | 男 | Director | 67 | 8.83万美元 | 33.04 | 2026-01-12 |
| Harith Rajagopalan | 男 | Chief Executive Officer and Director | 50 | 641.43万美元 | 263.10 | 2026-01-12 |
| Kelly Barnes | 女 | Director | 60 | 10.08万美元 | 13.94 | 2026-01-12 |
| Samuel Conaway | 男 | Director | 61 | 8.08万美元 | 5.25 | 2026-01-12 |
| Christopher Thompson | -- | Director | -- | 2.98万美元 | 1.50 | 2026-01-12 |
| William W. Bradley | 男 | Director | 82 | 8.33万美元 | 55.60 | 2026-01-12 |
| Amy W. Schulman | 女 | Director | 65 | 7.46万美元 | 未持股 | 2026-01-12 |
| Ian Sheffield | 男 | Director | 49 | 3.06万美元 | 5.00 | 2026-01-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harith Rajagopalan | 男 | Chief Executive Officer and Director | 50 | 641.43万美元 | 263.10 | 2026-01-12 |
| Jay D. Caplan | 男 | Co-Founder, President and Chief Product Officer | 65 | 304.30万美元 | 91.64 | 2026-01-12 |
| Timothy Kieffer | 男 | Chief Scientific Officer | 60 | 346.23万美元 | 未持股 | 2026-01-12 |
| Sarah Toomey | 女 | General Counsel and Corporate Secretary | 52 | 244.59万美元 | 39.34 | 2026-01-12 |
| Lara Smith Weber | 女 | Chief Financial Officer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2026-01-12 |
董事简历
中英对照 | 中文 | 英文- Marc Elia
-
Marc Elia自2022年6月起担任董事会成员，自2022年7月起担任董事会主席。他此前曾于2020年7月至2021年4月担任董事会成员。Elia先生是医疗保健行业投资基金M28 Capital Management L.P.的创始人兼首席投资官，自2019年9月以来一直担任该职位。在此之前，从2012年1月到2019年9月，埃利亚先生在投资基金Bridger Capital担任合伙人。埃利亚先生目前担任Fractyl Health，Inc.的董事会成员，该公司是一家公开上市的代谢疗法公司。他此前曾在SQZ生物技术公司和Adimab，LLC的董事会任职。在从事投资职业之前，Elia先生曾在N30 Pharmaceuticals、Chiron Corporation和L.E.K. Consulting的生物技术行业担任过各种职务。
Marc Elia has served as a member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors of Fractyl Health, Inc., a publicly traded metabolic therapeutics company. He previously served on the boards of directors of SQZ Biotechnologies Company and Adimab, LLC. Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting. - Marc Elia自2022年6月起担任董事会成员，自2022年7月起担任董事会主席。他此前曾于2020年7月至2021年4月担任董事会成员。Elia先生是医疗保健行业投资基金M28 Capital Management L.P.的创始人兼首席投资官，自2019年9月以来一直担任该职位。在此之前，从2012年1月到2019年9月，埃利亚先生在投资基金Bridger Capital担任合伙人。埃利亚先生目前担任Fractyl Health，Inc.的董事会成员，该公司是一家公开上市的代谢疗法公司。他此前曾在SQZ生物技术公司和Adimab，LLC的董事会任职。在从事投资职业之前，Elia先生曾在N30 Pharmaceuticals、Chiron Corporation和L.E.K. Consulting的生物技术行业担任过各种职务。
- Marc Elia has served as a member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors of Fractyl Health, Inc., a publicly traded metabolic therapeutics company. He previously served on the boards of directors of SQZ Biotechnologies Company and Adimab, LLC. Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting.
- Ajay Royan
-
Ajay Royan，自2025年3月起担任董事会成员，此前担任董事会成员的时间为2020年10月至2022年6月。Royan先生是创始人，自2012年6月起担任投资于科技公司的风险投资公司Mithril Capital Management LLC的管理普通合伙人。Royan先生目前担任代谢疗法公司Fractyl Health，Inc.的董事会成员，以及Mithril Capital Management LLC或其附属公司投资的几家私营公司的董事会成员，其中包括Adimab，LLC。Royan先生在Fulbright Canada的董事会任职。Royan先生获得了耶鲁大学的学士学位。
Ajay Royan,has served as a member of Board since March 2025, and he previously served as a member of Board from October 2020 until June 2022. Mr. Royan is the founder and has served as Managing General Partner of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012. Mr. Royan currently serves on the board of directors of Fractyl Health, Inc., a metabolic therapeutics company, as well as on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested, including Adimab, LLC. Mr. Royan serves on the board of directors of Fulbright Canada. Mr. Royan received a B.A. from Yale University. - Ajay Royan，自2025年3月起担任董事会成员，此前担任董事会成员的时间为2020年10月至2022年6月。Royan先生是创始人，自2012年6月起担任投资于科技公司的风险投资公司Mithril Capital Management LLC的管理普通合伙人。Royan先生目前担任代谢疗法公司Fractyl Health，Inc.的董事会成员，以及Mithril Capital Management LLC或其附属公司投资的几家私营公司的董事会成员，其中包括Adimab，LLC。Royan先生在Fulbright Canada的董事会任职。Royan先生获得了耶鲁大学的学士学位。
- Ajay Royan,has served as a member of Board since March 2025, and he previously served as a member of Board from October 2020 until June 2022. Mr. Royan is the founder and has served as Managing General Partner of Mithril Capital Management LLC, a venture capital firm investing in technology companies, since June 2012. Mr. Royan currently serves on the board of directors of Fractyl Health, Inc., a metabolic therapeutics company, as well as on the board of directors of several private companies in which Mithril Capital Management LLC or its affiliates have invested, including Adimab, LLC. Mr. Royan serves on the board of directors of Fulbright Canada. Mr. Royan received a B.A. from Yale University.
- Clive Meanwell
-
Clive Meanwell在选择和有效开发高质量的临床阶段制药资产以及通过美国和欧盟监管机构的批准降低这些资产的风险方面建立了成功的记录，同时创造了数百亿美元的股东价值，作为The Medicines Company的Founder兼首席执行官，Meanwell博士领导了对多个生物制药资产和公司的评估，收购或授权了14种候选产品和产品，包括6种适用于心血管药物，3种抗生素，以及5种用于手术和围手术期护理。The Medicines Company公司提出的所有8个产品候选进入III期临床试验，随后都获得了美国食品和药物管理局的批准，代表了100个III期临床试验的成功率。在他的领导下，The Medicines Company在生物制药公司中排名第一，在CNBC RQ 研究与开发生产力指数的所有行业中排名前五。
Clive Meanwell,has served as a member of Board since June 2021. Dr. Meanwell has also been a director and member of the compensation and audit committees at BB Biotech, a publicly-held Switzerland-based biotechnology investment company, since 2004, a director at EQRx, a privately-held biotechnology company aiming to make medicine more affordable, from January 2021 to August 2023, a director at Comanche BioPharma, a privately-held preclinical biopharmaceutical company developing treatments for preeclampsia, since 2021, a director at Hugo Health, a privately-held cloud-based healthcare platform, since 2021, a director at Invivyd, Inc. (previously Adagio Therapeutics, Inc.), a publicly-held biotechnology company developing antibodies against viruses, including potentially against COVID-19, since 2022, and a director at Saama, a privately-held company, since 2021. Dr. Meanwell also currently serves as the Executive Chairman of Metsera, Inc. a public biotechnology company focused on treating metabolic diseases and as Executive Chairman and General Partner at Population Health Partners LP, an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations. Dr. Meanwell also founded The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, and served as Executive Chairman and Chief Executive Officer from 1996 until 2018 and Chief Innovation Officer until 2020. Dr. Meanwell received his M.B., Ch.B. and M.D. from the University of Birmingham, UK. - Clive Meanwell在选择和有效开发高质量的临床阶段制药资产以及通过美国和欧盟监管机构的批准降低这些资产的风险方面建立了成功的记录，同时创造了数百亿美元的股东价值，作为The Medicines Company的Founder兼首席执行官，Meanwell博士领导了对多个生物制药资产和公司的评估，收购或授权了14种候选产品和产品，包括6种适用于心血管药物，3种抗生素，以及5种用于手术和围手术期护理。The Medicines Company公司提出的所有8个产品候选进入III期临床试验，随后都获得了美国食品和药物管理局的批准，代表了100个III期临床试验的成功率。在他的领导下，The Medicines Company在生物制药公司中排名第一，在CNBC RQ 研究与开发生产力指数的所有行业中排名前五。
- Clive Meanwell,has served as a member of Board since June 2021. Dr. Meanwell has also been a director and member of the compensation and audit committees at BB Biotech, a publicly-held Switzerland-based biotechnology investment company, since 2004, a director at EQRx, a privately-held biotechnology company aiming to make medicine more affordable, from January 2021 to August 2023, a director at Comanche BioPharma, a privately-held preclinical biopharmaceutical company developing treatments for preeclampsia, since 2021, a director at Hugo Health, a privately-held cloud-based healthcare platform, since 2021, a director at Invivyd, Inc. (previously Adagio Therapeutics, Inc.), a publicly-held biotechnology company developing antibodies against viruses, including potentially against COVID-19, since 2022, and a director at Saama, a privately-held company, since 2021. Dr. Meanwell also currently serves as the Executive Chairman of Metsera, Inc. a public biotechnology company focused on treating metabolic diseases and as Executive Chairman and General Partner at Population Health Partners LP, an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations. Dr. Meanwell also founded The Medicines Company, a biopharmaceutical company focused on addressing cardiovascular disease, and served as Executive Chairman and Chief Executive Officer from 1996 until 2018 and Chief Innovation Officer until 2020. Dr. Meanwell received his M.B., Ch.B. and M.D. from the University of Birmingham, UK.
- Harith Rajagopalan
-
Harith Rajagopalan，于2010年与他人共同创立了Fractyl，自2011年起担任Fractyl Health，Inc.首席执行官和Fractyl Health，Inc.董事会成员，同时于2009年至2011年担任General Catalyst Partners的常驻企业家。在创立Fractyl之前，Rajagopalan博士于2005年至2011年在马萨诸塞州波士顿的布莱根妇女医院接受内科和临床心脏病学培训，并于2009年至2011年在哈佛医学院完成研究奖学金。Rajagopalan博士在斯坦福大学获得化学学士学位，在约翰霍普金斯大学医学院获得医学博士和博士学位。
Harith Rajagopalan,co-founded Fractyl in 2010 and has served as Chief Executive Officer and a member of Board since 2011, while serving as an Entrepreneur-in-Residence at General Catalyst Partners from 2009 to 2011. Prior to founding Fractyl, Dr. Rajagopalan trained in internal medicine and clinical cardiology at Brigham and Women's Hospital in Boston, Massachusetts from 2005 to 2011, and completed a research fellowship at Harvard Medical School from 2009 to 2011. Dr. Rajagopalan received his B.S. in chemistry from Stanford University, and his M.D. and Ph.D. from Johns Hopkins University School of Medicine. - Harith Rajagopalan，于2010年与他人共同创立了Fractyl，自2011年起担任Fractyl Health，Inc.首席执行官和Fractyl Health，Inc.董事会成员，同时于2009年至2011年担任General Catalyst Partners的常驻企业家。在创立Fractyl之前，Rajagopalan博士于2005年至2011年在马萨诸塞州波士顿的布莱根妇女医院接受内科和临床心脏病学培训，并于2009年至2011年在哈佛医学院完成研究奖学金。Rajagopalan博士在斯坦福大学获得化学学士学位，在约翰霍普金斯大学医学院获得医学博士和博士学位。
- Harith Rajagopalan,co-founded Fractyl in 2010 and has served as Chief Executive Officer and a member of Board since 2011, while serving as an Entrepreneur-in-Residence at General Catalyst Partners from 2009 to 2011. Prior to founding Fractyl, Dr. Rajagopalan trained in internal medicine and clinical cardiology at Brigham and Women's Hospital in Boston, Massachusetts from 2005 to 2011, and completed a research fellowship at Harvard Medical School from 2009 to 2011. Dr. Rajagopalan received his B.S. in chemistry from Stanford University, and his M.D. and Ph.D. from Johns Hopkins University School of Medicine.
- Kelly Barnes
-
Kelly Barnes，自2022年1月起担任Fractyl Health，Inc.董事会成员。在加入Fractyl Health，Inc.之前，她曾于1988年至2020年在普华永道担任多个职务，最近于2018年至2020年担任全球健康行业领导者，并于2009年至2020年担任美国健康行业领导者，负责监督所有健康相关行业的服务。Barnes女士目前担任Included Health的董事会成员，并且是阿肯色大学沃尔顿商学院执行顾问委员会的成员。她获得了阿肯色大学会计学学士学位和硕士学位，是德克萨斯州的注册注册会计师。
Kelly Barnes,has served as a member of Board since January 2022. Prior to joining, she served in various roles at PricewaterhouseCoopers from 1988 to 2020, most recently serving as a Global Health Industries Leader from 2018 to 2020 and as a U.S. Health Industries Leader from 2009 to 2020, where she oversaw services across all health-related industries. Ms. Barnes currently serves on the board of directors of Included Health, a privately held company, and is a member of the executive advisory board of the Walton College of Business at the University of Arkansas. She received her B.S.B.A. and M.S.A in accounting from the University of Arkansas and is a registered certified public accountant in the state of Texas. - Kelly Barnes，自2022年1月起担任Fractyl Health，Inc.董事会成员。在加入Fractyl Health，Inc.之前，她曾于1988年至2020年在普华永道担任多个职务，最近于2018年至2020年担任全球健康行业领导者，并于2009年至2020年担任美国健康行业领导者，负责监督所有健康相关行业的服务。Barnes女士目前担任Included Health的董事会成员，并且是阿肯色大学沃尔顿商学院执行顾问委员会的成员。她获得了阿肯色大学会计学学士学位和硕士学位，是德克萨斯州的注册注册会计师。
- Kelly Barnes,has served as a member of Board since January 2022. Prior to joining, she served in various roles at PricewaterhouseCoopers from 1988 to 2020, most recently serving as a Global Health Industries Leader from 2018 to 2020 and as a U.S. Health Industries Leader from 2009 to 2020, where she oversaw services across all health-related industries. Ms. Barnes currently serves on the board of directors of Included Health, a privately held company, and is a member of the executive advisory board of the Walton College of Business at the University of Arkansas. She received her B.S.B.A. and M.S.A in accounting from the University of Arkansas and is a registered certified public accountant in the state of Texas.
- Samuel Conaway
-
Samuel Conaway，自2024年1月起担任Fractyl Health，Inc.董事会成员。Conaway先生目前还担任私人控股公司京东 Palatine LLC的董事。自2013年以来，Conaway先生在波士顿科学国际有限公司担任越来越重要的职务，该公司是一家上市公司，专注于医疗器械的全球开发、制造和营销。2021年10月，他成为美国心脏病学销售总裁。他目前还担任波士顿科学国际有限公司健康公平项目Close the Gap的主席。在加入波士顿科学国际有限公司之前，Conaway先生曾担任Abbott Vascular（前身为Guidant）的美国血管内和冠脉销售副总裁，该公司是一家上市生物医药公司雅培的心血管器械部门。康纳威先生在医疗器械行业拥有超过30年的经验。他在凤凰城大学获得了商业管理学士学位，并在马里兰大学获得了工商管理硕士学位。
Samuel Conaway,has served as a member of Board since January 2024. Mr. Conaway also currently serves as a director of JD Palatine LLC, a privately held company. Since 2013, Mr. Conaway has held roles of increasing responsibility with Boston Scientific Corporation, a publicly held company focused on global development, manufacturing and marketing of medical devices, and in October 2021, he became President of U.S cardiology sales. He also currently serves as chair of Close the Gap, Boston Scientific Corporation's health equity program. Prior to joining Boston Scientific Corporation, Mr. Conaway served as the Vice President of U.S. endovascular and coronary sales of Abbott Vascular (formerly Guidant), the cardiovascular device division of Abbott Laboratories, a publicly held biomedical company. Mr. Conaway has over 30 years of experience in the medical device industry. He received his B.S. in business management at the University of Phoenix and his M.B.A. at the University of Maryland. - Samuel Conaway，自2024年1月起担任Fractyl Health，Inc.董事会成员。Conaway先生目前还担任私人控股公司京东 Palatine LLC的董事。自2013年以来，Conaway先生在波士顿科学国际有限公司担任越来越重要的职务，该公司是一家上市公司，专注于医疗器械的全球开发、制造和营销。2021年10月，他成为美国心脏病学销售总裁。他目前还担任波士顿科学国际有限公司健康公平项目Close the Gap的主席。在加入波士顿科学国际有限公司之前，Conaway先生曾担任Abbott Vascular（前身为Guidant）的美国血管内和冠脉销售副总裁，该公司是一家上市生物医药公司雅培的心血管器械部门。康纳威先生在医疗器械行业拥有超过30年的经验。他在凤凰城大学获得了商业管理学士学位，并在马里兰大学获得了工商管理硕士学位。
- Samuel Conaway,has served as a member of Board since January 2024. Mr. Conaway also currently serves as a director of JD Palatine LLC, a privately held company. Since 2013, Mr. Conaway has held roles of increasing responsibility with Boston Scientific Corporation, a publicly held company focused on global development, manufacturing and marketing of medical devices, and in October 2021, he became President of U.S cardiology sales. He also currently serves as chair of Close the Gap, Boston Scientific Corporation's health equity program. Prior to joining Boston Scientific Corporation, Mr. Conaway served as the Vice President of U.S. endovascular and coronary sales of Abbott Vascular (formerly Guidant), the cardiovascular device division of Abbott Laboratories, a publicly held biomedical company. Mr. Conaway has over 30 years of experience in the medical device industry. He received his B.S. in business management at the University of Phoenix and his M.B.A. at the University of Maryland.
- Christopher Thompson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- William W. Bradley
-
William W. Bradley，他一直担任Fractyl Health, Inc.董事会成员（2017年3月以来）。自2000年以来，他一直担任Allen & Company LLC（一家投资银行公司）的董事总经理。从2001年到2004年，他担任麦肯锡公司非营利性业务的首席外部顾问。2000年，参议员布拉德利是民主党提名的美国总统候选人。从1997年到1999年，他担任JP Morgan & Co.国际理事会的高级顾问和副主席。在此期间，布拉德利还为哥伦比亚广播公司晚间新闻撰稿，并在斯坦福大学、圣母大学和马里兰大学担任客座教授。布拉德利参议员从1979年到1997年在美国参议院任职，代表新泽西州。在进入美国参议院之前，他是1964年奥运会的金牌得主，从1967年到1977年，他为纽约尼克斯队打职业篮球，在此期间他们赢得了两次世界冠军。他曾于2003年6月至2018年3月担任星巴克公司董事会成员。他还曾担任Seagate Technology、Willis Group Holdings Limited和qustreet, Inc.的董事会成员。他在普林斯顿大学获得美国历史学士学位，在牛津大学伍斯特学院获得政治哲学和经济学硕士学位，在那里他是罗德学者。
William W. Bradley,has served as a member of Board since March 2017. Since 2000, Sen. Bradley has been a managing director of Allen & Company LLC, an investment banking firm. From 2001 until 2004, he acted as chief outside advisor to McKinsey & Company's non-profit practice. In 2000, Sen. Bradley was a candidate for the Democratic nomination for President of the United States. He served as a senior advisor and vice chairman of the International Council of JP Morgan & Co. from 1997 through 1999. During that time, Sen. Bradley also worked as an essayist for CBS Evening News, and as a visiting professor at Stanford University, the University of Notre Dame and the University of Maryland. Sen. Bradley served in the U.S. Senate from 1979 until 1997, representing the State of New Jersey. Prior to serving in the U.S. Senate, he was an Olympic gold medalist in 1964, and from 1967 through 1977 he played professional basketball for the New York Knicks, during which time they won two world championships. Sen. Bradley previously served on the board of directors of Starbucks Corporation from June 2003 until March 2018. Sen. Bradley also previously served on the board of directors of Seagate Technology, Willis Group Holdings Limited and QuinStreet, Inc. Sen. Bradley received his B.A. in American history from Princeton University and his M.A. in political philosophy and economics from the University of Oxford, Worcester College, where he was a Rhodes Scholar. - William W. Bradley，他一直担任Fractyl Health, Inc.董事会成员（2017年3月以来）。自2000年以来，他一直担任Allen & Company LLC（一家投资银行公司）的董事总经理。从2001年到2004年，他担任麦肯锡公司非营利性业务的首席外部顾问。2000年，参议员布拉德利是民主党提名的美国总统候选人。从1997年到1999年，他担任JP Morgan & Co.国际理事会的高级顾问和副主席。在此期间，布拉德利还为哥伦比亚广播公司晚间新闻撰稿，并在斯坦福大学、圣母大学和马里兰大学担任客座教授。布拉德利参议员从1979年到1997年在美国参议院任职，代表新泽西州。在进入美国参议院之前，他是1964年奥运会的金牌得主，从1967年到1977年，他为纽约尼克斯队打职业篮球，在此期间他们赢得了两次世界冠军。他曾于2003年6月至2018年3月担任星巴克公司董事会成员。他还曾担任Seagate Technology、Willis Group Holdings Limited和qustreet, Inc.的董事会成员。他在普林斯顿大学获得美国历史学士学位，在牛津大学伍斯特学院获得政治哲学和经济学硕士学位，在那里他是罗德学者。
- William W. Bradley,has served as a member of Board since March 2017. Since 2000, Sen. Bradley has been a managing director of Allen & Company LLC, an investment banking firm. From 2001 until 2004, he acted as chief outside advisor to McKinsey & Company's non-profit practice. In 2000, Sen. Bradley was a candidate for the Democratic nomination for President of the United States. He served as a senior advisor and vice chairman of the International Council of JP Morgan & Co. from 1997 through 1999. During that time, Sen. Bradley also worked as an essayist for CBS Evening News, and as a visiting professor at Stanford University, the University of Notre Dame and the University of Maryland. Sen. Bradley served in the U.S. Senate from 1979 until 1997, representing the State of New Jersey. Prior to serving in the U.S. Senate, he was an Olympic gold medalist in 1964, and from 1967 through 1977 he played professional basketball for the New York Knicks, during which time they won two world championships. Sen. Bradley previously served on the board of directors of Starbucks Corporation from June 2003 until March 2018. Sen. Bradley also previously served on the board of directors of Seagate Technology, Willis Group Holdings Limited and QuinStreet, Inc. Sen. Bradley received his B.A. in American history from Princeton University and his M.A. in political philosophy and economics from the University of Oxford, Worcester College, where he was a Rhodes Scholar.
- Amy W. Schulman
-
Amy W. Schulman，自2018年9月起担任Fractyl Health, Inc.董事会成员。Schulman女士是Polaris Partners的医疗保健投资者和管理合伙人，也是Polaris Innovation Fund（成立于2017年）的联合创始人和管理合伙人。Schulman女士目前担任SQZ Biotech和Lyndra Therapeutics的执行主席，她共同创立了Lyndra Therapeutics，并于2015年7月至2019年9月担任该公司的首任首席执行官。在加入Polaris Partners之前，Schulman女士在Pfizer担任各种执行职务，包括总法律顾问、Pfizer Consumer Healthcare和Pfizer Nutrition总裁。Schulman女士目前是Alnylam Pharmaceuticals和Mount Sinai Hospital的董事会成员，也是新加坡健康和生物医学科学国际咨询委员会的成员。她曾担任Harvard Business School的高级讲师和DLA Piper的合伙人。她在Wesleyan University获得哲学和英语学士学位，以Phi Beta Kappa荣誉毕业，并在耶鲁大学法学院（Yale Law School）获得法学博士学位。
Amy W. Schulman has served as a member of board of directors since July 2014 and has served as chair of board since January 2023. Prior to that, she served as lead independent director from August 2021 to January 2023. Ms. Schulman joined Polaris Partners, a venture capital firm, in August 2014 where she is currently a managing partner. Ms. Schulman also served as Executive Chair of Lyndra Therapeutics, Inc., a biotechnology company, from September 2019 to March 2025, where she was co founder and served as the company's initial Chief Executive Officer from 2015 to 2019. She also manages the LS Polaris Innovation Fund, which was formed in 2017. Ms. Schulman served as a senior lecturer at Harvard Business School from July 2014 to July 2021, and resumed this role in January 2025. Ms. Schulman was previously the Executive Vice President and General Counsel of Pfizer from May 2008 to July 2014, where she also served as the Business Unit Lead for Pfizer's Consumer Healthcare business from 2012 to 2013. Before joining Pfizer, she was a partner at DLA Piper, a global law firm.Ms. Schulman also serves as a director of Elevance Health and previously served as a director of Fractyl Health, Inc., SQZ Biotech and Hudson Executive Investment Corp. II. - Amy W. Schulman，自2018年9月起担任Fractyl Health, Inc.董事会成员。Schulman女士是Polaris Partners的医疗保健投资者和管理合伙人，也是Polaris Innovation Fund（成立于2017年）的联合创始人和管理合伙人。Schulman女士目前担任SQZ Biotech和Lyndra Therapeutics的执行主席，她共同创立了Lyndra Therapeutics，并于2015年7月至2019年9月担任该公司的首任首席执行官。在加入Polaris Partners之前，Schulman女士在Pfizer担任各种执行职务，包括总法律顾问、Pfizer Consumer Healthcare和Pfizer Nutrition总裁。Schulman女士目前是Alnylam Pharmaceuticals和Mount Sinai Hospital的董事会成员，也是新加坡健康和生物医学科学国际咨询委员会的成员。她曾担任Harvard Business School的高级讲师和DLA Piper的合伙人。她在Wesleyan University获得哲学和英语学士学位，以Phi Beta Kappa荣誉毕业，并在耶鲁大学法学院（Yale Law School）获得法学博士学位。
- Amy W. Schulman has served as a member of board of directors since July 2014 and has served as chair of board since January 2023. Prior to that, she served as lead independent director from August 2021 to January 2023. Ms. Schulman joined Polaris Partners, a venture capital firm, in August 2014 where she is currently a managing partner. Ms. Schulman also served as Executive Chair of Lyndra Therapeutics, Inc., a biotechnology company, from September 2019 to March 2025, where she was co founder and served as the company's initial Chief Executive Officer from 2015 to 2019. She also manages the LS Polaris Innovation Fund, which was formed in 2017. Ms. Schulman served as a senior lecturer at Harvard Business School from July 2014 to July 2021, and resumed this role in January 2025. Ms. Schulman was previously the Executive Vice President and General Counsel of Pfizer from May 2008 to July 2014, where she also served as the Business Unit Lead for Pfizer's Consumer Healthcare business from 2012 to 2013. Before joining Pfizer, she was a partner at DLA Piper, a global law firm.Ms. Schulman also serves as a director of Elevance Health and previously served as a director of Fractyl Health, Inc., SQZ Biotech and Hudson Executive Investment Corp. II.
- Ian Sheffield
-
Ian Sheffield，2013年12月，他作为初始提名人加入Great Point Partners, LLC的董事会，并且目前担任Great Point Partners, LLC在格林威治分部的副总裁。作为他投资部门的一部分，他负责Great Point Partners公司的医疗设备和在公共公司的诊断方面的投资力度。从2008到2011年，在加入该公司之前，他曾在Versant Ventures的不同的生产部门任职；2011年之前，在美敦力公司和宝洁公司任职。他拥有迈阿密大学的学士学位和哈佛商学院工商管理硕士学位，也是审计委员会成员。
Ian Sheffield, joined the Board in December 2013 as an initial nominee of Great Point Partners, LLC and currently serves as a Vice President at Great Point Partners, Greenwich, CT. As part of his investment functions, he leads Great Point Partners' medical devices and diagnostics investing efforts in public companies. From 2008 through 2011 prior to joining Great Point, he served in various capacities at Versant Ventures, and prior to 2008 at Medtronic, and Procter & Gamble. He holds a B.S. from Miami University and an M.B.A. from the Harvard Business School and also serves as a member of Audit Committee. - Ian Sheffield，2013年12月，他作为初始提名人加入Great Point Partners, LLC的董事会，并且目前担任Great Point Partners, LLC在格林威治分部的副总裁。作为他投资部门的一部分，他负责Great Point Partners公司的医疗设备和在公共公司的诊断方面的投资力度。从2008到2011年，在加入该公司之前，他曾在Versant Ventures的不同的生产部门任职；2011年之前，在美敦力公司和宝洁公司任职。他拥有迈阿密大学的学士学位和哈佛商学院工商管理硕士学位，也是审计委员会成员。
- Ian Sheffield, joined the Board in December 2013 as an initial nominee of Great Point Partners, LLC and currently serves as a Vice President at Great Point Partners, Greenwich, CT. As part of his investment functions, he leads Great Point Partners' medical devices and diagnostics investing efforts in public companies. From 2008 through 2011 prior to joining Great Point, he served in various capacities at Versant Ventures, and prior to 2008 at Medtronic, and Procter & Gamble. He holds a B.S. from Miami University and an M.B.A. from the Harvard Business School and also serves as a member of Audit Committee.
高管简历
中英对照 | 中文 | 英文- Harith Rajagopalan
Harith Rajagopalan，于2010年与他人共同创立了Fractyl，自2011年起担任Fractyl Health，Inc.首席执行官和Fractyl Health，Inc.董事会成员，同时于2009年至2011年担任General Catalyst Partners的常驻企业家。在创立Fractyl之前，Rajagopalan博士于2005年至2011年在马萨诸塞州波士顿的布莱根妇女医院接受内科和临床心脏病学培训，并于2009年至2011年在哈佛医学院完成研究奖学金。Rajagopalan博士在斯坦福大学获得化学学士学位，在约翰霍普金斯大学医学院获得医学博士和博士学位。
Harith Rajagopalan,co-founded Fractyl in 2010 and has served as Chief Executive Officer and a member of Board since 2011, while serving as an Entrepreneur-in-Residence at General Catalyst Partners from 2009 to 2011. Prior to founding Fractyl, Dr. Rajagopalan trained in internal medicine and clinical cardiology at Brigham and Women's Hospital in Boston, Massachusetts from 2005 to 2011, and completed a research fellowship at Harvard Medical School from 2009 to 2011. Dr. Rajagopalan received his B.S. in chemistry from Stanford University, and his M.D. and Ph.D. from Johns Hopkins University School of Medicine.- Harith Rajagopalan，于2010年与他人共同创立了Fractyl，自2011年起担任Fractyl Health，Inc.首席执行官和Fractyl Health，Inc.董事会成员，同时于2009年至2011年担任General Catalyst Partners的常驻企业家。在创立Fractyl之前，Rajagopalan博士于2005年至2011年在马萨诸塞州波士顿的布莱根妇女医院接受内科和临床心脏病学培训，并于2009年至2011年在哈佛医学院完成研究奖学金。Rajagopalan博士在斯坦福大学获得化学学士学位，在约翰霍普金斯大学医学院获得医学博士和博士学位。
- Harith Rajagopalan,co-founded Fractyl in 2010 and has served as Chief Executive Officer and a member of Board since 2011, while serving as an Entrepreneur-in-Residence at General Catalyst Partners from 2009 to 2011. Prior to founding Fractyl, Dr. Rajagopalan trained in internal medicine and clinical cardiology at Brigham and Women's Hospital in Boston, Massachusetts from 2005 to 2011, and completed a research fellowship at Harvard Medical School from 2009 to 2011. Dr. Rajagopalan received his B.S. in chemistry from Stanford University, and his M.D. and Ph.D. from Johns Hopkins University School of Medicine.
- Jay D. Caplan
Jay D. Caplan，于2010年共同创立Fractyl，自2011年和2022年1月起分别担任Fractyl Health，Inc.总裁和首席产品官。他此前曾于2011年至2017年担任Fractyl Health，Inc.董事会成员。在创立Fractyl之前，Caplan先生曾于2007年11月至2010年1月担任Candela Corporation的首席运营官，该公司当时是一家美国上市的全球医疗美容设备公司。在加入Candela之前，他曾于2001年9月至2007年10月担任InfraReDx，Inc.的首席技术官和研发副总裁，该公司是一家设计和开发基于导管的冠状动脉成像设备的私营公司，后来被Nipro Corporation（日本）收购。Caplan先生此前还曾担任Thermo Cardiosystems Inc.（现为雅培的一部分）的运营副总裁，在那里他协助开发了HeartMate II左心室辅助设备。卡普兰先生在麻省理工学院（MIT）获得了电气工程学士学位，并在宾夕法尼亚大学沃顿商学院获得了工商管理硕士学位。
Jay D. Caplan,co-founded Fractyl in 2010 and has served as President and Chief Product Officer since 2011 and January 2022, respectively. He previously served as a member of Board of Directors from 2011 to 2017. Prior to founding Fractyl, Mr. Caplan served as Chief Operating Officer of Candela Corporation from November 2007 to January 2010, which was then a publicly held U.S.-based global medical aesthetic device company. Prior to Candela, he served as Chief Technology Officer and Vice President of Research and Development of InfraReDx, Inc. from September 2001 to October 2007, a privately held company that designs and develops catheter-based coronary imaging devices, that was later acquired by Nipro Corporation (Japan). Mr. Caplan also previously served as Vice President of Operations of Thermo Cardiosystems Inc. (now part of Abbott Laboratories), where he assisted in developing the HeartMate II left ventricular assist device. Mr. Caplan received his B.S. in electrical engineering from the Massachusetts Institute of Technology, or MIT, and his M.B.A. from the University of Pennsylvania's Wharton School of Business.- Jay D. Caplan，于2010年共同创立Fractyl，自2011年和2022年1月起分别担任Fractyl Health，Inc.总裁和首席产品官。他此前曾于2011年至2017年担任Fractyl Health，Inc.董事会成员。在创立Fractyl之前，Caplan先生曾于2007年11月至2010年1月担任Candela Corporation的首席运营官，该公司当时是一家美国上市的全球医疗美容设备公司。在加入Candela之前，他曾于2001年9月至2007年10月担任InfraReDx，Inc.的首席技术官和研发副总裁，该公司是一家设计和开发基于导管的冠状动脉成像设备的私营公司，后来被Nipro Corporation（日本）收购。Caplan先生此前还曾担任Thermo Cardiosystems Inc.（现为雅培的一部分）的运营副总裁，在那里他协助开发了HeartMate II左心室辅助设备。卡普兰先生在麻省理工学院（MIT）获得了电气工程学士学位，并在宾夕法尼亚大学沃顿商学院获得了工商管理硕士学位。
- Jay D. Caplan,co-founded Fractyl in 2010 and has served as President and Chief Product Officer since 2011 and January 2022, respectively. He previously served as a member of Board of Directors from 2011 to 2017. Prior to founding Fractyl, Mr. Caplan served as Chief Operating Officer of Candela Corporation from November 2007 to January 2010, which was then a publicly held U.S.-based global medical aesthetic device company. Prior to Candela, he served as Chief Technology Officer and Vice President of Research and Development of InfraReDx, Inc. from September 2001 to October 2007, a privately held company that designs and develops catheter-based coronary imaging devices, that was later acquired by Nipro Corporation (Japan). Mr. Caplan also previously served as Vice President of Operations of Thermo Cardiosystems Inc. (now part of Abbott Laboratories), where he assisted in developing the HeartMate II left ventricular assist device. Mr. Caplan received his B.S. in electrical engineering from the Massachusetts Institute of Technology, or MIT, and his M.B.A. from the University of Pennsylvania's Wharton School of Business.
- Timothy Kieffer
Timothy Kieffer，自2023年9月起担任Fractyl Health，Inc.首席科学官。在加入Fractyl Health，Inc.之前，Kieffer博士曾于2021年9月至2022年10月担任ViaCyte Inc.的首席科学官，该公司是一家处于糖尿病干细胞衍生治疗前沿的私营公司。他目前还担任不列颠哥伦比亚大学细胞和生理科学与外科的医学教授，自2007年以来一直担任该职位。Kieffer博士的研究专注于胰岛生物学以及治疗糖尿病的新型基因和细胞疗法方法的开发，他与人合著了200多篇关于这些主题的出版物，被引用超过20,000次。他在不列颠哥伦比亚大学获得生理学博士学位。
Timothy Kieffer,has served as Chief Scientific Officer since September 2023. Prior to joining, Dr. Kieffer served as the Chief Scientific Officer of ViaCyte Inc., a privately held company at the forefront of stem cell-derived treatments for diabetes, from September 2021 to October 2022. In September 2024 Dr. Kieffer co-founded Lunar Therapeutics, a privately held company formed with the goal of developing novel strategies for stem cell-derived treatments for diabetes, where he also serves as a member of the board of directors. He also currently serves as a Professor of Medicine in the department of cellular and physiological sciences and surgery at the University of British Columbia, a position he has held since 2007. Dr. Kieffer's research is focused on islet biology and the development of novel gene and cell therapy approaches to treat diabetes, and he has co-authored more than 200 publications on these topics and has been cited over 20,000 times. He received his Ph.D. in physiology from the University of British Columbia.- Timothy Kieffer，自2023年9月起担任Fractyl Health，Inc.首席科学官。在加入Fractyl Health，Inc.之前，Kieffer博士曾于2021年9月至2022年10月担任ViaCyte Inc.的首席科学官，该公司是一家处于糖尿病干细胞衍生治疗前沿的私营公司。他目前还担任不列颠哥伦比亚大学细胞和生理科学与外科的医学教授，自2007年以来一直担任该职位。Kieffer博士的研究专注于胰岛生物学以及治疗糖尿病的新型基因和细胞疗法方法的开发，他与人合著了200多篇关于这些主题的出版物，被引用超过20,000次。他在不列颠哥伦比亚大学获得生理学博士学位。
- Timothy Kieffer,has served as Chief Scientific Officer since September 2023. Prior to joining, Dr. Kieffer served as the Chief Scientific Officer of ViaCyte Inc., a privately held company at the forefront of stem cell-derived treatments for diabetes, from September 2021 to October 2022. In September 2024 Dr. Kieffer co-founded Lunar Therapeutics, a privately held company formed with the goal of developing novel strategies for stem cell-derived treatments for diabetes, where he also serves as a member of the board of directors. He also currently serves as a Professor of Medicine in the department of cellular and physiological sciences and surgery at the University of British Columbia, a position he has held since 2007. Dr. Kieffer's research is focused on islet biology and the development of novel gene and cell therapy approaches to treat diabetes, and he has co-authored more than 200 publications on these topics and has been cited over 20,000 times. He received his Ph.D. in physiology from the University of British Columbia.
- Sarah Toomey
Sarah Toomey，自2022年5月起担任Fractyl Health，Inc.总法律顾问和公司秘书。在加入Fractyl Health，Inc.之前，Toomey女士于2017年10月至2022年5月担任BERG LLC或BERG（现为BPGBio，Inc.）的高级运营副总裁兼总法律顾问，BERG LLC或BERG（现为BPGBio，Inc.）是一家临床阶段人工智能驱动的生物制药公司，专注于肿瘤学、神经病学和罕见病。在加入BERG之前，Toomey女士于2015年4月至2017年10月担任Metamark Genetics的总法律顾问，Metamark Genetics是一家专注于泌尿外科癌症护理的分子诊断公司。Toomey女士还曾于2009年2月至2015年1月在IntelligentMDX公司担任高级副总裁兼总法律顾问，该公司是一家开发和制造分子诊断产品的公司。Toomey女士是一名注册专利律师，在成为内部法律顾问之前曾从事专利法工作。在上法学院之前，Toomey女士曾受雇于默沙东，担任微生物学家。Toomey女士获得了威斯康星大学麦迪逊分校的细菌学学士学位和萨福克大学法学院的法学博士学位。
Sarah Toomey,has served as General Counsel and Corporate Secretary since May 2022. Prior to joining, Ms. Toomey was Senior Vice President of Operations and General Counsel of BERG LLC or BERG (now BPGbio, Inc.), a clinical-stage AI-powered biopharmaceutical company focused on oncology, neurology and rare diseases, from October 2017 to May 2022. Prior to BERG, Ms. Toomey was General Counsel at Metamark Genetics, a molecular diagnostics company focused on urological cancer care, from April 2015 to October 2017. Ms. Toomey also previously served as Senior Vice President and General Counsel at IntelligentMDx, a company that developed and manufactured molecular diagnostics products, from February 2009 to January 2015. Ms. Toomey is a registered patent attorney and practiced patent law before becoming in-house counsel. Prior to law school, Ms. Toomey was employed at Merck as a microbiologist. Ms. Toomey received her B.S. in bacteriology from the University of Wisconsin-Madison and her J.D. from Suffolk University Law School.- Sarah Toomey，自2022年5月起担任Fractyl Health，Inc.总法律顾问和公司秘书。在加入Fractyl Health，Inc.之前，Toomey女士于2017年10月至2022年5月担任BERG LLC或BERG（现为BPGBio，Inc.）的高级运营副总裁兼总法律顾问，BERG LLC或BERG（现为BPGBio，Inc.）是一家临床阶段人工智能驱动的生物制药公司，专注于肿瘤学、神经病学和罕见病。在加入BERG之前，Toomey女士于2015年4月至2017年10月担任Metamark Genetics的总法律顾问，Metamark Genetics是一家专注于泌尿外科癌症护理的分子诊断公司。Toomey女士还曾于2009年2月至2015年1月在IntelligentMDX公司担任高级副总裁兼总法律顾问，该公司是一家开发和制造分子诊断产品的公司。Toomey女士是一名注册专利律师，在成为内部法律顾问之前曾从事专利法工作。在上法学院之前，Toomey女士曾受雇于默沙东，担任微生物学家。Toomey女士获得了威斯康星大学麦迪逊分校的细菌学学士学位和萨福克大学法学院的法学博士学位。
- Sarah Toomey,has served as General Counsel and Corporate Secretary since May 2022. Prior to joining, Ms. Toomey was Senior Vice President of Operations and General Counsel of BERG LLC or BERG (now BPGbio, Inc.), a clinical-stage AI-powered biopharmaceutical company focused on oncology, neurology and rare diseases, from October 2017 to May 2022. Prior to BERG, Ms. Toomey was General Counsel at Metamark Genetics, a molecular diagnostics company focused on urological cancer care, from April 2015 to October 2017. Ms. Toomey also previously served as Senior Vice President and General Counsel at IntelligentMDx, a company that developed and manufactured molecular diagnostics products, from February 2009 to January 2015. Ms. Toomey is a registered patent attorney and practiced patent law before becoming in-house counsel. Prior to law school, Ms. Toomey was employed at Merck as a microbiologist. Ms. Toomey received her B.S. in bacteriology from the University of Wisconsin-Madison and her J.D. from Suffolk University Law School.
- Lara Smith Weber
Lara Smith Weber，于2023年10月至2026年1月11日担任Inari的首席财务官，在那里她完成了多笔融资，加强了公司的资本结构，并构建了财务系统和流程，以支持不断发展的组织。此前，从2022年6月至2023年9月，她担任ONWARD Medical的首席财务官，该公司是一家在布鲁塞尔泛欧交易所、阿姆斯特丹泛欧交易所和巴黎泛欧交易所上市的上市医疗技术公司。从2013年10月到2022年5月，Smith Weber女士在MorphoSys担任的财务领导职务责任越来越大，包括从2021年2月到2022年5月担任美国首席财务官和商业财务主管，在那里她在组织筹备成为一家商业阶段公司并作为该公司运营方面发挥了关键作用。Smith Weber女士拥有德国研究和电气工程学士学位、斯坦福大学电气工程硕士学位和瑞士IMD MBA学位。
Lara Smith Weber,served as Chief Financial Officer of Inari from October 2023 to January 11, 2026, where she completed multiple financings, strengthened the company's capital structure, and built financial systems and processes to support a growing organization. Previously, from June 2022 to September 2023, she was Chief Financial Officer of ONWARD Medical, a publicly traded medtech company listed on Euronext Brussels, Euronext Amsterdam and Euronext Paris. From October 2013 to May 2022, Ms. Smith Weber held finance leadership roles of increasing responsibility at MorphoSys, including serving as U.S. Chief Financial Officer and Head of Commercial Finance from February 2021 to May 2022, where she played a key role in preparing the organization for and operating as a commercial-stage company. Ms. Smith Weber holds bachelor's degrees in German Studies and Electrical Engineering, a master's degree in Electrical Engineering from Stanford University, and an MBA from IMD in Switzerland.- Lara Smith Weber，于2023年10月至2026年1月11日担任Inari的首席财务官，在那里她完成了多笔融资，加强了公司的资本结构，并构建了财务系统和流程，以支持不断发展的组织。此前，从2022年6月至2023年9月，她担任ONWARD Medical的首席财务官，该公司是一家在布鲁塞尔泛欧交易所、阿姆斯特丹泛欧交易所和巴黎泛欧交易所上市的上市医疗技术公司。从2013年10月到2022年5月，Smith Weber女士在MorphoSys担任的财务领导职务责任越来越大，包括从2021年2月到2022年5月担任美国首席财务官和商业财务主管，在那里她在组织筹备成为一家商业阶段公司并作为该公司运营方面发挥了关键作用。Smith Weber女士拥有德国研究和电气工程学士学位、斯坦福大学电气工程硕士学位和瑞士IMD MBA学位。
- Lara Smith Weber,served as Chief Financial Officer of Inari from October 2023 to January 11, 2026, where she completed multiple financings, strengthened the company's capital structure, and built financial systems and processes to support a growing organization. Previously, from June 2022 to September 2023, she was Chief Financial Officer of ONWARD Medical, a publicly traded medtech company listed on Euronext Brussels, Euronext Amsterdam and Euronext Paris. From October 2013 to May 2022, Ms. Smith Weber held finance leadership roles of increasing responsibility at MorphoSys, including serving as U.S. Chief Financial Officer and Head of Commercial Finance from February 2021 to May 2022, where she played a key role in preparing the organization for and operating as a commercial-stage company. Ms. Smith Weber holds bachelor's degrees in German Studies and Electrical Engineering, a master's degree in Electrical Engineering from Stanford University, and an MBA from IMD in Switzerland.